Nevro Corp NVRO:NYSE

Last Price$43.51Cboe Real-Time Last Sale as of 3:54PM ET 12/05/22
Cboe Real-Time Quotes
Realtime quote and/or trade prices are not sourced from all markets
Today's Change-1.68(3.72%)
Bid (Size)$43.47 (200)
Ask (Size)$43.53 (5)
Day Low / High$43.41 - 45.03
Volume247.1 K

View Medical Specialties IndustryPeer Comparison as of 12/05/2022


Nevro Corp ( NYSE )

Price: $43.51
Change: -1.68 (3.72%)
Volume: 247.1 K
3:54PM ET 12/05/2022

Owens & Minor Inc ( NYSE )

Price: $20.80
Change: -0.23 (1.12%)
Volume: 282.6 K
3:54PM ET 12/05/2022

Myriad Genetics Inc ( NASDAQ )

Price: $19.86
Change: -1.07 (5.09%)
Volume: 354.5 K
3:53PM ET 12/05/2022

Meridian Bioscience Inc ( NASDAQ )

Price: $31.99
Change: -0.01 (0.03%)
Volume: 79.4 K
3:54PM ET 12/05/2022

Avanos Medical Inc ( NYSE )

Price: $26.60
Change: -0.52 (1.92%)
Volume: 121.3 K
3:54PM ET 12/05/2022

Read more news Recent News

--Piper Sandler Adjusts Price Target on Nevro to $42 From $45, Maintains Neutral Rating
12:36PM ET 11/03/2022 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

-- Earnings Flash (NVRO) NEVRO Posts Q3 Revenue $86.1M, vs. Street Est of $99.2M
4:15PM ET 11/02/2022 MT Newswires


Nevro Says FDA Approved Its Senza HFX iQ Spinal Cord Stimulation System
4:23AM ET 10/13/2022 MT Newswires

Nevro (NVRO) said Wednesday the US Food and Drug Administration has approved its Senza HFX iQ spinal cord stimulation system. The company said the...

Nevro Shares Down After Jefferies Initiates Coverage at Underperform
11:42AM ET 10/12/2022 MT Newswires

Nevro (NVRO) shares were down 4.9% around midday Wednesday after Jefferies initiated coverage with an underperform rating and a $31 price target. Trading...

View all Commentary and Analysis

Nevro: Recent Developments Corroborate Breakout, Revise To Buy
3:55AM ET 12/01/2022 Seeking Alpha

Here's Why You Should Hold on to Nevro (NVRO) Stock Now
11:09AM ET 11/30/2022 Zacks

Investors continue to be optimistic about Nevro (NVRO), owing to its strength in the global SCS...

Nevro Corporation (NVRO) Q3 2022 Earnings Call Transcript
2:22AM ET 11/03/2022 Seeking Alpha

Nevro Corp. 2022 Q3 - Results - Earnings Call Presentation
11:24PM ET 11/02/2022 Seeking Alpha

Company Profile

Business DescriptionNevro Corp. engages in the provision of medical devices. The firm focuses on providing products that improve the quality of life of patients suffering from debilitating chronic pain. It develops and commercializes senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain. The company was founded by Konstantinos Alataris in March 2006 and is headquartered in Redwood City, CA. View company web site for more details
Address1800 Bridge Parkway
Redwood City, California 94065
Number of Employees804
Recent SEC Filing11/15/20224
Chairman, President & Chief Executive OfficerD. Keith Grossman
Chief Financial OfficerRoderick H. MacLeod
Chief Medical OfficerDavid Caraway
Vice President-Technical OperationsChristopher Christoforou

Company Highlights

Price Open$44.17
Previous Close$45.19
52 Week Range$34.70 - 98.12
Market Capitalization$1.5 B
Shares Outstanding35.4 M
SectorHealth Technology
IndustryMedical Specialties
Next Earnings Announcement02/22/2023

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$2.33
Beta vs. S&P 500N/A
Revenue$387.3 M
Net Profit Margin-2.01%
Return on Equity-2.89%

Analyst Ratings as of 10/10/2022

Consensus RecommendationConsensus Icon
Powered by Factset